Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer

Journal of Pathology

Volumn 190, Issue 1, 2000, Pages 20-30

  Müllauer, Leonhard ^a   Mosberger, Isabella ^a   Grusch, Michael ^a   Rudas, Margarete ^a   Chott, Andreas ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; Breast cancer; Fas; Fas ligand; Immune surveillance; Tumour invasion

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INVASION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSURVEILLANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANTIGENS, CD95; ANTIGENS, NUCLEAR; APOPTOSIS; BLOTTING, WESTERN; BREAST; BREAST DISEASES; BREAST NEOPLASMS; CARRIER PROTEINS; COCULTURE TECHNIQUES; DNA FRAGMENTATION; FAS LIGAND PROTEIN; FEMALE; HUMANS; JURKAT CELLS; MEMBRANE GLYCOPROTEINS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTEIN-TYROSINE-PHOSPHATASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0342979787     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(200001)190:1<20::AID-PATH497>3.0.CO;2-S     Document Type: Article

References (39)

1. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365.
2. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178.
3. Leithäuser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993; 4: 415-429.
4. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630-632.
5. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-1192.
6. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand expressing tumor cells - a mechanism of immune evasion? Nature Med 1996; 2: 1361-1366.
7. Hahne M, Rimoldi D, Schröter M, et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363-1366.
8. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-1082.
9. Niehans GA, Brunner T, Frizelle SP, et al. Human lung carcinomas express fas ligand. Cancer Res 1997; 57: 1007-1012.
10. Saas P, Walker PR, Hahne M, et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 1997; 99: 1173-1178.
11. Gratas C, Tohma Y, Van Meir EG, et al. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol 1997; 7: 863-869.
12. Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 1995; 16: 569-574.
13. Keane MM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowitz S. Fas expression and function in normal and malignant breast cell lines. Cancer Res 1996; 56: 4791-4798.
14. Bargou RC, Daniel PT, Mapara MY, et al. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-α expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 1995; 60: 854-859.
15. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973; 51: 1409-1416.
16. Castles CG, Fuqua SA, Klotz DM, Hill SM. Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res 1993; 53: 5934-5939.
17. Gillis S, Watson J. Biochemical and biological characterization of lymphocyte regulatory molecules. V. Identification of an interleukin 2-producing human leukemia T cell line. J Exp Med 1980; 152: 1709-1719.
18. Herr I, Balemans L, Böhler T, Walczak H, Debatin KM. Monitoring of CD95 (APO-1/Fas) ligand expression in human T cells by quantitative RT-PCR. Cell Death Differ 1996; 3: 299-305.
19. Müllauer L, Mosberger I, Chott A. Fas ligand expression in nodal non-Hodgkin's lymphoma. Mod Pathol 1998; 11: 369-375.
20. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation. J Cell Biol 1992; 3: 493-501.
21. Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759-1762.
22. Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995; 154: 2706-2713.
23. Sato T, Irie S, Kitada S, Reed JC. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995; 268: 411-415.
24. Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nature Med 1996; 2: 317-322.
25. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nature Med 1998; 4: 31-36.
26. Oyaizu N, Kayagaki N, Yagita H, Pahwa S, Ikawa Y. Requirement of cell cell contact in the induction of Jurkat T cell apoptosis: the membrane-anchored but not soluble form of FasL can trigger anti-CD3-induced apoptosis in Jurkat T cells. Biochem Biophys Res Commun 1997; 238: 670-675.
27. Kurokawa H, Nishio K, Fukumoto H, Tomonari A, Suzuki T, Saijo N. Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7, breast cancer cells. Oncol Rep 1999; 6(1): 33-37.
28. Ferguson DJ, Anderson TJ. Morphological evaluation of cell turnover in relation to the menstrual cycle in the resting human breast. Br J Cancer 1981; 44: 177-181.
29. Batterby S, Anderson TJ. Proliferative and secretory activity in the pregnant and lactating human breast. Virchows Arch A [Pathol Anat Histopathol] 1988; 413: 189-196.
30. Suzuki A, Enari M, Eguchi Y, et al. Involvement of Fas in regression of vaginal epithelia after ovariectomy and during an estrous cycle. EMBO J 1996; 15: 211-215.
31. Lipponen P, Aaltomaa S, Kosma VM, Syrjänen K. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer 1994; 30A: 2068-2073.
32. Richardson BC, Lalwani ND, Johnson KJ, Marks RM. Fas ligation triggers apoptosis in macrophages but not endothelial cells. Eur J Immunol 1994; 24: 2640-2645.
33. Dhein J, Walczak H, Bäumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by Apo-1/(Fas/CD95). Nature 1995; 373: 438-441.
34. Arai H, Chan SY, Bishop DK, Nabel GJ. Inhibition of the alloantibody response by CD95 ligand. Nature Med 1997; 3: 843-848.
35. Arai H, Gordon D, Nabel EG, Nabel GJ. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci U S A 1997; 94: 13862-13867.
36. Seino K, Kayagaki N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nature Med 1997; 3: 165-170.
37. Lau HT, Stoeckert CJ. FasL - too much of a good thing? Nature Med 1997; 7: 727-728.
38. Chen J-J, Sun Y, Nabel GJ. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998; 282: 1714-1717.
39. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical staining for transforming growth factor β1 associates with disease progression in human breast cancer. Cancer Res 1992; 52: 6949-6952.